Gruppo Biomed Mod

Gruppo Biomed Mod is a foreign owned, non-profit organization that is registered to receive awards from the U.S. federal government. Through past federal grants, Gruppo Biomed Mod has provided medical research services focused on understanding the mechanisms that lead to diabetes. Specifically, they have conducted research examining the role of impaired glucagon suppression in diabetes progression, under prime awards from the Mayo Clinic. This research has investigated the effects of genetic variants associated with type 2 diabetes, such as TCF7L2, on glucagon suppression and pancreatic cell dysfunction over time. The aim has been to elucidate the relationship between impaired glucagon suppression and declining pancreatic cell function in the pathogenesis of prediabetes and progression to overt diabetes. Gruppo Biomed Mod has also provided mathematical modeling services, through a subaward from the University of Missouri System, to model clinical tests of glucose metabolism and insulin secretion. This modeling aims to provide improved methods for measuring insulin action, secretion, and glucose homeostasis in vivo. Overall, through both prime and subawards, Gruppo Biomed Mod has focused its federally funded work on furthering understanding of diabetes pathogenesis and improving diagnostic testing methods.